GMMMG logo

NHS photos

NHS logo

Shared Care Guidelines in Development

 

On this page you will find all Shared Care Guidelines that are currently going through the GMMMG approval process as well as those that have been authored by GMMMG. You will be able to comment on current Shared Care Guidelines out for consultation via the links in the table below.

Pathway Title

Information

Feedback

End date

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, the Shared Care Guidelines for DMARDs in Rheumatology listed below are in development following updated drug monitoring guidelines in January 2017 from the British Society of Rheumatology.

We now seek the comments of all GM NHS healthcare professionals on these drafts This consultation period is open until 5.00pm Friday
1st Sep 2017. Comments should be submitted via the appropriate Feedback Form link after which they will be reviewed, amended as required and then taken to GMMMG for final approval. The Pharmaceutical Industry is invited to comment on factual inaccuracies only.

01

Azathioprine

View Azathioprine document

Azathioprine Feedback Form

5.00pm Friday
1st Sep 2017

02

Ciclosporin

View Ciclosporin document

Ciclosporin Feedback Form

5.00pm Friday
1st Sep 2017

03

Hydroxychloroquine

View Hydroxychloroquine document

Hydroxychloroquine Feedback Form

5.00pm Friday
1st Sep 2017

04

Leflunomide

View Leflunomide document

LeflunomideFeedback Form

5.00pm Friday
1st Sep 2017

05

Methotrexate (oral)

View Methotrexate (oral) document

Methotrexate (oral) Feedback Form

5.00pm Friday
1st Sep 2017

06

Mycophenolate

View Mycophenolate document

MycophenolateFeedback Form

5.00pm Friday
1st Sep 2017

07

Sodium Aurothiomalate

View Sodium Aurothiomalate document

Sodium Aurothiomalate Feedback Form

5.00pm Friday
1st Sep 2017

08

Sulfasalazine

View Sulfasalazine document

Sulfasalazine Feedback Form

5.00pm Friday
1st Sep 2017

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer